Biosimilars

COVID-19

Cataract Surgery

Cataract

Cataract Therapeutics

NeuroOp Guru

The Residency Report

iOpeners

Clinical Diagnosis

Cornea

Dry Eye Awareness

Dry Eye

Gene Therapy

Geographic Atrophy

IOL Advances

Imaging

Glaucoma Awareness

Glaucoma Insights

Therapeutic Glaucoma

Interventional Glaucoma

Ocular Allergy

Ocular Surface Disease

Optic Relief

Optometry

Pediatrics

Pharmacy

Indispensable

Practice Management

Presbyopia

Ptosis

Refractive Surgery

Refractive

Retina

Surgery

Technology

Therapeutics

Understanding Antibiotic Resistance

Workplace

News

All News

Contributors

Money Matters

Media

All Videos

Expert Interviews

Medical World News

Podcasts

Case Based Roundtable Series

Case of the Quarter

EyeView

Grand Rounds

Insights

Rapid Readout

Viewpoints

What’s Your WhEYE?

Conferences

Conference Coverage

Conference Listing

Events

Publications

Digital Edition

Europe Ophthalmology Times

Modern Retina

Supplements and Featured Publications

Partners

Subscribe

Resources

Job Board

Articles

Sandoz received FDA approval for its biosimilar Enzeevu (aflibercept-abzv) on August 12, 2024. It has the same dosage form, route of administration, and presentation as the reference medicine, Eylea from Regeneron.

Sandoz and Regeneron reach agreement over biosimilar dispute

Professor of ophthalmology at the Wilmer Eye Institute in Johns Hopkins University in Baltimore, Maryland

Videos

Using OCT-A to explore biomarkers for neurodegenerative diseases

This update from UHC includes procedures enabled with its OMNI Surgical System technology from Sight Sciences.

UnitedHealthcare updates Glaucoma Surgical Treatments policy

In both trials, Beacon’s lead program, laru-zova, was found to be well-tolerated by SKYLINE participants through month 36 and DAWN patients at month 9 or longer.

Beacon Therapeutics reports positive phase 2 results for gene therapy in X-linked retinitis pigmentosa

Ophthalmology Times connects eye care professionals with surgery, imaging, gene therapy, & diagnostic advances to enhance clinical and patient care.

About

Advertise

Privacy

Editorial Info

Editorial Board

Terms and Conditions

Contact Us

Do Not Sell My Personal Information

Ophthalmology Times – Clinical Insights for Eye Specialists

Facebook

Instagram

LinkedIn

Spotlight

Clinical

Glaucoma

View

Rochester, NY-The decision to perform a biopsy and whether the biopsy is bilateral or unilateral can be difficult in arteritic anterior ischemic optic neuropathy (AAION).

Biopsy advisable in AAION if high degree of clinical suspicion present

Biopsy advisable in AAION if high degree of clinical suspicion present

Newsletter